{"id":65,"date":"2018-11-30T12:23:52","date_gmt":"2018-11-30T12:23:52","guid":{"rendered":"https:\/\/admin.innaxon.co.uk\/?page_id=65"},"modified":"2018-11-30T12:23:52","modified_gmt":"2018-11-30T12:23:52","slug":"literature","status":"publish","type":"page","link":"https:\/\/wp.innaxon.co.uk\/?page_id=65","title":{"rendered":"Literature"},"content":{"rendered":"

IAXO-101 (CD14\/TLR4 Antagonist) (synthetic)<\/strong><\/a><\/h1>\n

[1]\u00a0Glycolipids and benzylammonium lipids as novel antisepsis agents: synthesis and biological characterization<\/i>. Piazza M, et al. J. Med. Chem. (2009); 52:1209
\n[2]\u00a0Glia TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice.\u00a0<\/i>Bettoni I, et al. Glia (2008); 56:1312
\n[3] Inhibition of lipid a stimulated activation of human dendritic cells and macrophages by amino and hydroxylamino monosaccharides.\u00a0<\/i>
\nPeri F, et al. Angew .Chem. (2007); 46:3308
\n[4]\u00a0Evidence of a specific interaction between new synthetic antisepsis agents and CD14.\u00a0<\/i>Piazza M, et al. Biochemistry (2009); 48:12337
\n[5]\u00a0Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists.\u00a0<\/i>Peri F, Piazza M. Biotechnol. Adv. (2012); 30:251 REVIEW
\n[6]\u00a0Synthetic molecules and functionalized nanoparticles targeting the LPS-TLR4 signaling: A new generation of immunotherapeutics.\u00a0<\/i>Peri F, Calabrese V, Piazza M, Cighetti R.Pure Appl. Chem. (2012); 84:97 REVIEW
\n[7]\u00a0Inhibition of the cluster of differentiation 14 innate immunity pathway with IAXO-101 improves chronic microelectrode performance<\/em>.\u00a0<\/i>Hermann JK., et al. J Neural Eng (2017) [Epub ahead of print]\u00a0PubMed Abstract<\/a><\/p>\n

IAXO-102 (CD14\/TLR4 Antagonist) (synthetic)<\/strong><\/a><\/h1>\n

[1]\u00a0TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice.<\/i>\u00a0Bettoni I, et al. Glia (2008); 56:1312
\n[2]\u00a0Exploring the LPS\/TLR4 signal pathway with small molecules.<\/i>\u00a0Peri F, et al.; Biochem Soc Trans. (2010); 38:1390 REVIEW
\n[3]\u00a0Toll like receptor 4 antagonist prevents acetaminophen induced acute liver failure in mice: a novel therapeutic strategy.\u00a0<\/i>Shah N, et al.; Gut (2012); 61:A28
\n[4]\u00a0Multivalent glycoconjugates as anti-pathogenic agents.<\/i>\u00a0Bernardi A, et al.; Chem Soc Rev. (2013); 42:4709 REVIEW
\n[5]\u00a0Toll-like receptor 4 (TLR4) modulation by synthetic and natural compounds: an update.<\/i>\u00a0Peri F, Calabrese V. Med Chem. (2014); 57:3612 REVIEW
\n[6]\u00a0A novel small molecule TLR4 antagonist (IAXO-102) negatively regulates non-hematopoietic toll like receptor 4 signalling and inhibits aortic aneurysms development..\u00a0<\/i>Huggins C, et al. Atherosclerosis. 242:563 (2015).\u00a0\"\"\u00a0Journal Article<\/a>
\n[7]\u00a0Synthetic and natural small molecule TLR4 antagonists inhibit motoneuron death in cultures from ALS mouse model.<\/i>\u00a0De Paola M, et al. Pharmacol Res. 103:180 (2016)\u00a0Pubmed Abstract<\/a>
\n[8]\u00a0Effects of Toll-Like Receptor 4 Antagonists Against Cerebral Vasospasm After Experimental Subarachnoid Hemorrhage in Mice.\u00a0<\/i>Kawakita F., et al.\u00a0Mol Neurobiol 54:6624-6633 (2017)\u00a0Pubmed Abstract<\/a><\/p>\n

IAXO-103 (CD14\/TLR4 Antagonist) (synthetic)<\/strong><\/a><\/h1>\n

[1]\u00a0Glycolipids and benzylammonium lipids as novel antisepsis agents: synthesis and biological characterization<\/i>.
\nPiazza M, et al. J. Med. Chem. (2009); 52:1209
\n[2]\u00a0Evidence of a specific interaction between new synthetic antisepsis agents and CD14.\u00a0<\/i>Piazza M, et al. Biochemistry (2009); 48:12337
\n[3]\u00a0Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists.<\/i>\u00a0Peri F, Piazza M. Biotechnol. Adv. (2012); 30:251 REVIEW
\n[4]\u00a0Exploring the LPS\/TLR4 signal pathway with small molecules.<\/i>\u00a0Peri F, et al.; Biochem Soc Trans. (2010); 38:1390 REVIEW
\n[5]\u00a0Multivalent glycoconjugates as anti-pathogenic agents<\/i>. Bernardi A, et al.; Chem Soc Rev. (2013); 42:4709 REVIEW
\n[6]\u00a0Toll-like receptor 4 (TLR4) modulation by synthetic and natural compounds: an update.<\/i>\u00a0Peri F, Calabrese V. Med Chem. (2014); 57:3612 REVIEW<\/p>\n

IAXO-201 (Control for IAXO-102) (synthetic)<\/strong><\/a><\/h1>\n

[1] Glycolipids and benzylammonium lipids as novel antisepsis agents: synthesis and biological characterization. Piazza M, et al. J. Med. Chem. (2009); 52:1209
\n[2] Inhibition of lipid a stimulated activation of human dendritic cells and macrophages by amino and hydroxylamino monosaccharides. Peri F, et al. Angew .Chem. (2007); 46:3308
\n[3] Evidence of a specific interaction between new synthetic antisepsis agents and CD14. Piazza M, et al. Biochemistry (2009); 48:12337
\n[4] Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists. Peri F, Piazza M. Biotechnol. Adv. (2012); 30:251 REVIEW
\n[5] Synthetic molecules and functionalized nanoparticles targeting the LPS-TLR4 signaling: A new generation of immunotherapeutics. Peri F, Calabrese V, Piazza M, Cighetti R. Pure Appl. Chem. (2012); 84:97 REVIEW<\/p>\n

IAXO-202 (Control for IAXO-101 \/ IAXO-103) (synthetic)<\/strong><\/a><\/h1>\n

[1]\u00a0Glycolipids and benzylammonium lipids as novel antisepsis agents: synthesis and biological characterization<\/i>. Piazza M, et al. J. Med. Chem. (2009); 52:1209
\n[2] Inhibition of lipid a stimulated activation of human dendritic cells and macrophages by amino and hydroxylamino monosaccharides.\u00a0<\/i>
\nPeri F, et al. Angew .Chem. (2007); 46:3308
\n[3]\u00a0Evidence of a specific interaction between new synthetic antisepsis agents and CD14.\u00a0<\/i>Piazza M, et al. Biochemistry (2009); 48:12337
\n[4]\u00a0Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists.\u00a0<\/i>Peri F, Piazza M. Biotechnol. Adv. (2012); 30:251 REVIEW
\n[5]\u00a0Synthetic molecules and functionalized nanoparticles targeting the LPS-TLR4 signaling: A new generation of immunotherapeutics.\u00a0<\/i>Peri F, Calabrese V, Piazza M, Cighetti R.Pure Appl. Chem. (2012); 84:97 REVIEW
\n\u200b\u200b\u200b\u200b\u200b\u200b\u200b<\/p>\n

\n

Need additional information?<\/strong>
\nPlease get in touch via email: info@innaxon.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

IAXO-101 (CD14\/TLR4 Antagonist) (synthetic) [1]\u00a0Glycolipids and benzylammonium lipids as novel antisepsis agents: synthesis and biological characterization. Piazza M, et al. J. Med. Chem. (2009); 52:1209 [2]\u00a0Glia TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice.\u00a0Bettoni I, et al. Glia (2008); […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-65","page","type-page","status-publish","hentry"],"yoast_head":"\nLiterature -<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/wp.innaxon.co.uk\/?page_id=65\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Literature -\" \/>\n<meta property=\"og:description\" content=\"IAXO-101 (CD14\/TLR4 Antagonist) (synthetic) [1]\u00a0Glycolipids and benzylammonium lipids as novel antisepsis agents: synthesis and biological characterization. Piazza M, et al. J. Med. Chem. (2009); 52:1209 [2]\u00a0Glia TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice.\u00a0Bettoni I, et al. Glia (2008); […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/wp.innaxon.co.uk\/?page_id=65\" \/>\n<meta property=\"og:image\" content=\"http:\/\/youraccount.ekmpowershop27.com\/ekmps\/shops\/bioaxxess3\/images\/pdf-image%5Bekm%5D20x20%5Bekm%5D.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/wp.innaxon.co.uk\/?page_id=65\",\"url\":\"https:\/\/wp.innaxon.co.uk\/?page_id=65\",\"name\":\"Literature -\",\"isPartOf\":{\"@id\":\"https:\/\/wp.innaxon.co.uk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/wp.innaxon.co.uk\/?page_id=65#primaryimage\"},\"image\":{\"@id\":\"https:\/\/wp.innaxon.co.uk\/?page_id=65#primaryimage\"},\"thumbnailUrl\":\"http:\/\/youraccount.ekmpowershop27.com\/ekmps\/shops\/bioaxxess3\/images\/pdf-image[ekm]20x20[ekm].png\",\"datePublished\":\"2018-11-30T12:23:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/wp.innaxon.co.uk\/?page_id=65#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/wp.innaxon.co.uk\/?page_id=65\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/wp.innaxon.co.uk\/?page_id=65#primaryimage\",\"url\":\"http:\/\/youraccount.ekmpowershop27.com\/ekmps\/shops\/bioaxxess3\/images\/pdf-image[ekm]20x20[ekm].png\",\"contentUrl\":\"http:\/\/youraccount.ekmpowershop27.com\/ekmps\/shops\/bioaxxess3\/images\/pdf-image[ekm]20x20[ekm].png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/wp.innaxon.co.uk\/?page_id=65#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/wp.innaxon.co.uk\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Literature\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/wp.innaxon.co.uk\/#website\",\"url\":\"https:\/\/wp.innaxon.co.uk\/\",\"name\":\"\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/wp.innaxon.co.uk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Literature -","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/wp.innaxon.co.uk\/?page_id=65","og_locale":"en_GB","og_type":"article","og_title":"Literature -","og_description":"IAXO-101 (CD14\/TLR4 Antagonist) (synthetic) [1]\u00a0Glycolipids and benzylammonium lipids as novel antisepsis agents: synthesis and biological characterization. Piazza M, et al. J. Med. Chem. (2009); 52:1209 [2]\u00a0Glia TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice.\u00a0Bettoni I, et al. Glia (2008); […]","og_url":"https:\/\/wp.innaxon.co.uk\/?page_id=65","og_image":[{"url":"http:\/\/youraccount.ekmpowershop27.com\/ekmps\/shops\/bioaxxess3\/images\/pdf-image[ekm]20x20[ekm].png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/wp.innaxon.co.uk\/?page_id=65","url":"https:\/\/wp.innaxon.co.uk\/?page_id=65","name":"Literature -","isPartOf":{"@id":"https:\/\/wp.innaxon.co.uk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/wp.innaxon.co.uk\/?page_id=65#primaryimage"},"image":{"@id":"https:\/\/wp.innaxon.co.uk\/?page_id=65#primaryimage"},"thumbnailUrl":"http:\/\/youraccount.ekmpowershop27.com\/ekmps\/shops\/bioaxxess3\/images\/pdf-image[ekm]20x20[ekm].png","datePublished":"2018-11-30T12:23:52+00:00","breadcrumb":{"@id":"https:\/\/wp.innaxon.co.uk\/?page_id=65#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/wp.innaxon.co.uk\/?page_id=65"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/wp.innaxon.co.uk\/?page_id=65#primaryimage","url":"http:\/\/youraccount.ekmpowershop27.com\/ekmps\/shops\/bioaxxess3\/images\/pdf-image[ekm]20x20[ekm].png","contentUrl":"http:\/\/youraccount.ekmpowershop27.com\/ekmps\/shops\/bioaxxess3\/images\/pdf-image[ekm]20x20[ekm].png"},{"@type":"BreadcrumbList","@id":"https:\/\/wp.innaxon.co.uk\/?page_id=65#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/wp.innaxon.co.uk\/"},{"@type":"ListItem","position":2,"name":"Literature"}]},{"@type":"WebSite","@id":"https:\/\/wp.innaxon.co.uk\/#website","url":"https:\/\/wp.innaxon.co.uk\/","name":"","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/wp.innaxon.co.uk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"_links":{"self":[{"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/pages\/65","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65"}],"version-history":[{"count":1,"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/pages\/65\/revisions"}],"predecessor-version":[{"id":66,"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=\/wp\/v2\/pages\/65\/revisions\/66"}],"wp:attachment":[{"href":"https:\/\/wp.innaxon.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}